Araştırmacı Derya ÖNEL

Yayın Ağı

Makaleler 18

1. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels

Ormeci A., Aydın Y., Sumnu A., Baran B., Soyer O. M., Pinarbasi B., et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , cilt.52, ss.68-73, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

2. Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study

Soyer O. M., Baran B., Ormeci A., Gokturk S., Aydin E., Onel D., et al.

POSTGRADUATE MEDICINE , cilt.128, sa.4, ss.432-438, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

3. Steroid-refractory inflammatory bowel disease is a risk factor for CMV infection

Ormeci A., Akyuz F., BARAN B., SOYER O., GÖKTÜRK S., ONEL M., et al.

European Review for Medical and Pharmacological Sciences , cilt.20, sa.5, ss.858-865, 2016 (SCI-Expanded)

4. Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., et al.

LIVER INTERNATIONAL , cilt.35, sa.10, ss.2265-2274, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

5. Effects of Polymorphisms in Interferon lambda 3 (Interleukin 28B) on Sustained Virologic Response to Therapy in Patients With Chronic Hepatitis D Virus Infection

Yilmaz E., Baran B., Soyer O. M., Onel M., Onel D., Ormeci A., et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY , cilt.12, sa.10, ss.1753-1758, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

6. Acute hepatitis B due to immune-escape mutations in a naturally immune patient

Kaymakoglu S., Baran B., Onel D., Badur S., Atamer T., Akyuz F.

ACTA GASTRO-ENTEROLOGICA BELGICA , sa.2, ss.262-265, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

7. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B

KESKİN O., Ormeci A., Baran B., Kabacam G., Tuzun A., Karatayli E., et al.

ANTIVIRAL THERAPY , cilt.19, sa.6, ss.543-550, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

8. Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients

Mese S., Arikan M., Cakiris A., Abaci N., Gumus E., Kursun O., et al.

JOURNAL OF GENERAL VIROLOGY , cilt.94, ss.2729-2738, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

9. Efficacy of Tenofovir in Patients with Lamivudine Failure Is Not Different from That in Nucleoside/Nucleotide Analogue-Naive Patients with Chronic Hepatitis B

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Bozbey H. U., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.57, sa.4, ss.1790-1796, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

10. Prevalence and virological features of occult hepatitis B virus infection in female sex workers who work uncontrolled in Turkey.

Pinarbasi B., Onel D., Cosan F., Akyuz F., Dirlik N., Cakaloglu Y., et al.

Liver international : official journal of the International Association for the Study of the Liver , cilt.29, sa.2, ss.227-30, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

11. Acute hepatitis A virus infection in Turkey

Normann A., Badur S., Oenel D., Kılıç A., Sidal M., Larouze B., et al.

JOURNAL OF MEDICAL VIROLOGY , cilt.80, sa.5, ss.785-790, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

12. Mutations in influenza A virus (H5N1) and possible limited spread, Turkey, 2006

Altiok E., Taylan F., Yenen O. Ş., Demirkeser G., Bozaci M., Oenel D., et al.

EMERGING INFECTIOUS DISEASES , cilt.14, sa.3, ss.491-492, 2008 (SCI-Expanded)

13. Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B

Kaymakoglu S., Danalioglu A., Demir K., Karaca C., Akyuz F., Onel D., et al.

Digestive Diseases and Sciences , cilt.52, sa.3, ss.727-731, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

14. Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy

Akyuz F., Kaymakoglu S., Demir K., Aksoy N., Karaca C., Danalioglu A., et al.

Acta Gastro-Enterologica Belgica , cilt.70, sa.1, ss.20-24, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

15. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection

Besisik F., Karaca Q., Akyuz F., Horosanli S., Onel D., Badur S., et al.

JOURNAL OF HEPATOLOGY , cilt.38, sa.4, ss.506-510, 2003 (SCI-Expanded) Sürdürülebilir Kalkınma

16. Age-specific seroepidemiology of hepatitis A, B, and E infections among children in Istanbul, Turkey

Sidal M., Unuvar E., Oguz F., Cihan C., Onel D., Badur S.

EUROPEAN JOURNAL OF EPIDEMIOLOGY , cilt.17, sa.2, ss.141-144, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

17. Immunization of renal transplant recipients with pneumococcal polysaccharide vaccine

Kazancioglu R., Sever M., Yuksel-Onel D., Eraksoy H., Yildiz A., Celik A., et al.

CLINICAL TRANSPLANTATION , cilt.14, sa.1, ss.61-65, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

18. Immune response to Haemophilus influenzae type b vaccination in renal transplant recipients with well-functioning allografts

Sever M., Yildiz A., Eraksoy H., Badur S., Yuksel-Onel D., Gorcin B., et al.

NEPHRON , cilt.81, sa.1, ss.55-59, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 17

1. Tenofovir disoproxil fumarate has a substantial efficacy against adefovir and multi-drug resistant strains of hepatitis B virus

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., et al.

64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, (Özet Bildiri) Sürdürülebilir Kalkınma

2. Risk factors for significant liver fibrosis in genotype D HBeAg-negative chronic hepatitis B infection with persistently normal ALT and high serum HBVDNA levels

Ormeci A., Akyuz F., Baran B., Soyer O. M., Gokturk S., Karaca C., et al.

64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, (Özet Bildiri) Sürdürülebilir Kalkınma

3. The antiviral efficacy of entecavir is not influenced by prior treatment with nucleos(t)ide analogues in patients with chronic hepatitis B

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., et al.

64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, (Özet Bildiri)

4. IL28B Polymorphisms and Influence on Sustained Virological Response to Interferon Therapy in Chronic DELTA Hepatitis.

Karaca C., Yılmaz E., Mutluay Soyer O., Onel D., Onel M., Baran B., et al.

Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), Orlando, Amerika Birleşik Devletleri, 18 - 21 Mayıs 2013, cilt.144, sa.5, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

5. IL28B Polymorphisms and Influence on Sustained Virological Response to Interferon Therapy in Chronic DELTA Hepatitis

Karaca C., Yilmaz E., Soyer O. M., Onel D., ÖNEL M., Baran B., et al.

Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), Florida, Amerika Birleşik Devletleri, 18 - 21 Mayıs 2013, cilt.144, (Özet Bildiri) Sürdürülebilir Kalkınma

6. Investigation of resistance mutations in the HBV DNA samples that isolated from patients with chronic Hepatitis nucleoside/nucleotide analogues by INNO-LIPA HBV DR and ultradeep pyrosequencing methods

MEŞE S., ARIKAN M., ÇAKİRİS A., ABACI N., ÖNEL D., USTEK D., et al.

2nd World Congress on Virology, Las Vegas, Amerika Birleşik Devletleri, 20 - 22 Ağustos 2012, cilt.4, sa.4, ss.147, (Tam Metin Bildiri) Sürdürülebilir Kalkınma